Kalaris Therapeutics, Inc. (KLRS): Cash & Equivalents
$98.05M
As of 2025-12-31
$43.17M
As of 2026-06-30
-2.6%
3-year compound annual growth
-4.4%
5-year compound annual growth
| Period ended | Cash & Equivalents | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $98.05M | n/m | 2026-03-17, Balance as of period end |
| 2024-12-31 | $1.64M | -98.2% | 2026-03-17, Balance as of period end |
| 2023-12-31 | $90.12M | -15.1% | 2025-03-07, Balance as of period end |
| 2022-12-31 | $106.09M | -47.4% | 2024-03-15, Balance as of period end |
| 2021-12-31 | $201.66M | +64.4% | 2023-02-15, Balance as of period end |
| 2020-12-31 | $122.66M | +100.8% | 2022-02-10, Balance as of period end |
| 2019-12-31 | $61.08M | n/a | 2021-02-12, Balance as of period end |
Cash & Equivalents at similar companies
| Company | Year ended | Cash & Equivalents | Change YoY |
|---|---|---|---|
| Kalaris Therapeutics, Inc. (KLRS) | 2025-12-31 | $98.05M | n/m |
| Acumen Pharmaceuticals, Inc. (ABOS) | 2025-12-31 | $53.99M | +51.5% |
| Candel Therapeutics, Inc. (CADL) | 2025-12-31 | $119.73M | +16.6% |
| Humacyte, Inc. (HUMA) | 2025-12-31 | $50.50M | +12.4% |
| Zura Bio Ltd (ZURA) | 2025-12-31 | $109.41M | -38.0% |
| Pelthos Therapeutics Inc. (PTHS) | 2025-12-31 | $17.97M | n/m |
| Artiva Biotherapeutics, Inc. (ARTV) | 2025-12-31 | $26.70M | -33.6% |
| Lineage Cell Therapeutics, Inc. (LCTX) | 2025-12-31 | $40.79M | -10.9% |
| Palisade Bio, Inc. (PALI) | 2025-12-31 | $133.38M | n/m |
Compare KLRS, ABOS, CADL, HUMA side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗